CDT6, also known by its gene name ANGPTL7, is a fascinating protein that has garnered attention for its role in the intricate processes of vascular development and extracellular matrix organization, particularly within the ocular environment. This protein has been observed to have an expression pattern that suggests it plays a part in the maintenance of corneal clarity and avascularity, a critical aspect for normal vision. Understanding the regulation of CDT6 is a topic of ongoing research with the aim of elucidating the complex network of signals that govern angiogenesis and the structural integrity of the extracellular matrix. The expression of CDT6, like many genes, is subject to a symphony of regulatory mechanisms, including transcriptional control by various biochemical signals within the cellular milieu. In the quest to clarify these regulatory pathways, a number of chemical activators have been hypothesized to potentially induce the expression of CDT6.
The landscape of these chemical activators is diverse, encompassing compounds that engage with a wide array of cellular receptors and signaling pathways. For instance, retinoic acid, a metabolite of vitamin A, is well-documented for its role in gene transcription via retinoic acid receptors and could be a candidate for upregulating CDT6. Another compound, sulforaphane, which is known for its role in activating the Nrf2 pathway, may also hold the potential to enhance CDT6 expression as a protective response against oxidative stress. Additionally, forskolin, through its elevation of cAMP levels, could conceivably influence the transcriptional machinery to favor CDT6 expression. Molecules like resveratrol, with its ability to activate SIRT1, might also contribute to a similar upregulation, leveraging pathways associated with longevity and cardiovascular health. It is important to note that while these chemicals are postulated to interact with pathways that could lead to increased CDT6 expression, the exact mechanisms remain to be fully elucidated. Investigating the relationship between these compounds and CDT6 is a promising area of research that could enhance our understanding of the regulation of angiogenesis and extracellular matrix composition, shedding light on the intricate web of interactions that sustain physiological processes crucial for maintaining the structural and functional integrity of vascular tissues.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid might upregulate CDT6 expression by binding to nuclear receptors that initiate transcription of genes involved in angiogenesis, potentially including CDT6. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide could stimulate CDT6 production as a response to its anti-angiogenic properties, resulting in a compensatory increase in angiogenic mediators. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $150.00 $286.00 $479.00 $1299.00 $8299.00 $915.00 | 22 | |
DL-Sulforaphane may enhance CDT6 expression by activating the Nrf2 pathway, leading to a protective response against oxidative damage in vascular tissues. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Hydroxychloroquine may trigger an increase in CDT6 expression due to its ability to concentrate in acidic vesicles and potentially alter intracellular signaling cascades. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $70.00 $160.00 $290.00 | 2 | |
Cholecalciferol could promote CDT6 transcription by its metabolite calcitriol which binds to the Vitamin D receptor, activating gene expression related to vascular homeostasis. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
β-Estradiol may induce CDT6 expression by estrogen receptor-mediated transcriptional activation of genes crucial for maintaining corneal avascularity. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Pioglitazone might stimulate CDT6 production through PPAR-gamma-mediated transcriptional activation of genes linked to angiogenesis and extracellular matrix composition. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin could potentially upregulate CDT6 expression by increasing intracellular cAMP, which may enhance the activity of transcription factors involved in angiogenic processes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol may upregulate CDT6 expression due to its ability to activate SIRT1, which in turn could stimulate genes associated with angiogenesis and vascular protection. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone could stimulate CDT6 expression by activating glucocorticoid receptors that lead to an upregulation of genes governing ocular tissue integrity and avascularity. |